tbuckley/cabot-search huggingface dataset:
OP0084 Serum fibroblast growth factor 2 is a useful biomarker to distinguish adult onset still disease from sepsis
Authors: T. Koga, R. Sumiyoshi, S. Sato, K. Migita, T. Shimizu, M. Umeda, F. Nonaka, S. Fukui, S.-Y. Kawashiri, N. Iwamoto, K. Ichinose, M. Tamai, H. Nakamura, T. Origuchi, A. Yachie, T. Maeda, A. Kawakami
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The precise cytokine networks in the serum of individuals with adult onset still disease (AOSD) that are associated with its pathogenesis have been unknown. Serum levels of interleukin (IL)−1β, IL-6 and IL-18 have been reported as useful serum biomarkers for diagnosis and disease evaluation among AOSD patients,<sup>1 2</sup> but these cytokines are also elevated in other inflammatory diseases including severe infection. <h3>Objectives</h3> We attempted to identify specific biomarkers to distinguish AOSD from sepsis. <h3>Methods</h3> We measured serum levels of 45 cytokines in 66 AOSD patients, 17 sepsis patients and 133 age-matched controls by multi-suspension cytokine array. Japan College of Rheumatology-certified rheumatologists diagnosed with AOSD based on the Yamaguchi criteria. Cytokines were ranked by their importance by a multivariate classification algorithm. We performed a logistic regression analysis to determine specific biomarkers for discriminating AOSD from sepsis patients. To identify specific molecular networks, we performed a cluster analysis of each cytokine. <h3>Results</h3> Serum fibroblast growth factor 2<b> (</b>FGF-2), vascular endothelial growth factor (VEGF), granulocyte-colony stimulating factor (G-CSF), and IL-18 levels were significantly elevated in the AOSD group versus the sepsis group. Multivariate classification algorithms followed by a logistic regression analysis revealed that the measurement FGF-2 distinguished AOSD patients from sepsis patients with the highest accuracy (cut-off value=28.5 pg/mL, sensitivity 100%, specificity 88.2%, accuracy 96.7%). <h3>Conclusions</h3> We have demonstrated that FGF-2 can be the best biomarker for differential diagnosis between AOSD and sepsis based on the measurement of multiple cytokines. Although the differential diagnosis between rheumatic diseases and infectious conditions is a great challenge in clinical practice, these findings help to improve the diagnostic performance of AOSD in daily practice. <h3>References</h3> [1] Clin Exp Rheumatol. 1996Nov–Dec;14(6):653–5. [2] Rheumatology (<i>Oxford)</i>2016Dec;55(12):2237–2247. <h3>Disclosure of Interest</h3> None declared
Abstract 19829: Efficacy of Intensive Periodontal Therapy in Primary Prevention Of Dental Hypertension Development: A Randomized Controlled Clinical Trial
Authors: Jun Tao, Junying Yang, Qianbing Zhou, Wenhao Xia, Jing Ren, Chen Su, Xiaoyu Zhang
Journal: Circulation (2017)

Background: Previous studies showed that there is a linkage between periodontitis and hypertension, however, direct clinical evidence is lacking. We conducted a prospective intervention clinical tr...
Magnet Patterned Superparamagnetic Fe<sub>3</sub>O<sub>4</sub>/Au Core–Shell Nanoplasmonic Sensing Array for Label‐Free High Throughput Cytokine Immunoassay
Authors: Yuxin Cai, Jingyi Zhu, Jiacheng He, Wen Yang, Chao Ma, Feng Xiong, Feng Li, Weiqiang Chen, Pengyu Chen
Journal: Advanced Healthcare Materials (2019)

Rapid and accurate immune monitoring plays a decisive role in effectively treating immune-related diseases especially at point-of-care, where an immediate decision on treatment is needed upon precise determination of the patient immune status. Derived from the emerging clinical demands, there is an urgent need for a cytokine immunoassay that offers unprecedented sensor performance with high sensitivity, throughput, and multiplexing capability, as well as short turnaround time at low system complexity, manufacturability, and scalability. In this paper, a label-free, high throughput cytokine immunoassay based on a magnet patterned Fe
Sertraline or placebo in chronic breathlessness? Lessons from placebo research
Authors: David C. Currow, Meera Agar, Magnus Ekström
Journal: European Respiratory Journal (2019)

K. Pattinson and V. Wanigasekera raise important questions about understanding better the placebo response. This effectiveness study randomised people to either double-blind sertraline or placebo [1]. The study reported a response rate in the placebo arm (change in breathlessness now) almost mirroring that for sertraline. However, this observed change in the control group needs to be distinguished from any placebo response. There are at least two factors which are difficult to quantify but are likely to account for the vast majority of improved breathlessness that was seen in the control and intervention arms: the Hawthorne effect [2]; and regression to the mean [3]. Any placebo response is likely to be a very small component of the response rate in the placebo arm. A small proportion of the response in the placebo arm is likely to be attributable to a true "placebo response" <http://ow.ly/XLwI30naUWP>
Dysfunctional ErbB2, an EGF receptor family member, hinders repair of airway epithelial cells from asthmatic patients
Authors: Hideki Inoue, Takeshi Hattori, Xiuxia Zhou, Emily B. Etling, Brian D. Modena, John B. Trudeau, Fernando Holguin, Sally E. Wenzel
Journal: Journal of Allergy and Clinical Immunology (2019)
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
Authors: Florian von Groote-Bidlingmaier, Ramonde Patientia, Epifanio Sanchez, Vincent Balanag, Eduardo Ticona, Patricia Segura, Elizabeth Cadena, Charles Yu, Andra Cirule, Victor Lizarbe, Edita Davidaviciene, Liliana Domente, Ebrahim Variava, Janice Caoili, Manfrid Danilovits, Virgaine Bielskiene, Suzanne Staples, Norbert Hittel, Carolyn Petersen, Charles Wells, Jeffrey Hafkin, Lawrence J Geiter, Rajesh Gupta
Journal: The Lancet Respiratory Medicine (2019)
AB1119 Clinical, therapeutic characterisation and time to achive remission analysis of a colombian cohort with juvenile idiopathic myopathy
Authors: R. Fuentes, M. Cañola, J.C. Diaz-Coronado, A. Rojas-Villarraga, D. Hernandez-Parra, P. Perez-Estrada, J.C. Salazar-Uribe, R. Pineda-Tamayo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The clinical characteristics of paediatric patients with idiopathic inflammatory myopathies difere from adutls in several aspects. Its clinical presentation can include amyopathic onset and the skin involvement has diferent charecteristics <h3>Objectives</h3> To describe a Colombian cohort with Juvenile Myositis (JM) recruited in a rheumatology facility. <h3>Methods</h3> A cross-section retrospective research with data collected between 2014 and 2017 from a population diagnosed before 16 years of age with Idiopathic Myopathy according to Peter and Bohan criteria and followed up for at least six months. Kaplan-Meier curves were performed to analize time to achieve remission. <h3>Results</h3> Out of 37 patients, one was excluded for having a dystrophy myopathy gene, 73% fulfilled definitive and 16% probable Bohan and Peter criteria; most patients were female 75,8%,<sup>28</sup> with mean age of onset 7,2 years, and clinical remission was achieved on average at 4 years of disease. There was high prevalence of Gottron's sign and papules (89%), Heliotrope rash (62%) and Calcinosis (37%). Other involvements are described in Table 1. Antinuclear antibodies were positive in 52%. Electromyography (EMG) was positive for myopathy in 39% of the patients. Biopsy was compatible with myopathy in 10% and was negative in 32% of the patients. The most common treatment was metrothexate (91%) followed by antimalarials (72%) and corticoids (56,7%). Medication used in severe forms included Cyclophosphamide (5%), Rituximab (16%) and IV Immunoglobulin (5%). Kaplan-Meier curves showed an earlier time to remmision in patients with Gottron sign compared to patients without them (HR:8,25 HR CI95%IL:1,076–63,3;p=0042 and in childrens younger than 15 years compared to older patients (HR: 2,529 HR95%IL: 1,084–5,901, p: 0,039). <h3>Conclusions</h3> Our results agreed with those obtained in other multi-centred studies including latin america that evaluated clinical and therapeutic characteristics in children with myopathy, Gottron's sign and papules being the most common findings and with high rates of calcinosis and joint involvement. There was a significant difference between remission lapse in patients younger than 15 years compared to older ones. <h3>Reference</h3> [1] , D. Guseinova, et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clinical and Experimental Rheumatology2011; 29: 117–124 <h3>Disclosure of Interest</h3> None declared
Tuberculosis following PD-1 blockade for cancer immunotherapy
Authors: Daniel L. Barber, Shunsuke Sakai, Ragini R. Kudchadkar, Steven P. Fling, Tracey A. Day, Julie A. Vergara, David Ashkin, Jonathan H. Cheng, Lisa M. Lundgren, Vanessa N. Raabe, Colleen S. Kraft, Jorge J. Nieva, Martin A. Cheever, Paul T. Nghiem, Elad Sharon
Journal: Science Translational Medicine (2019)

Increased Mtb-specific T H 1 responses precede tuberculosis associated with PD-1 blockade.
Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial
Authors: Rama Kandasamy, Meeru Gurung, Stephen Thorson, Ly-Mee Yu, Ushma Galal, Merryn Voysey, Sarah Kelly, Brian Wahl, Guy Berbers, Kier Finnegan, Imran Ansari, Krishna Paudel, David R Murdoch, Katherine L O'Brien, Dominic F Kelly, David Goldblatt, Shrijana Shrestha, Andrew J Pollard
Journal: The Lancet Infectious Diseases (2019)
AB0440 Ethnic minorities experience infrequent biologic switch despite active rheumatoid arthritis disease
Authors: G. Kerr, C. Swearingen, S. Hochberg, J. Ude, Y. Yazici
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The expanded therapeutic modalities in rheumatoid arthritis (RA) provide options to achieve low disease activity or remission. Yet, in routine care, the frequency and choice of switching of biologic DMARD (bDMARD) amongst ethnic subsets when there is inefficacy, is unknown. <h3>Objectives</h3> To evaluate frequency and choice of biologic switch in ethnic RA subsets <h3>Methods</h3> Patients enrolled in the Ethnic Minority RA Consortium (EMRAC), with at least one followup visit were analysed. Data included clinical outcomes as assessed by RAPID3 tender/swollen joint counts; medication use (prednisone, methotrexate, other DMARD), and bDMARD (Tumour Necrosis factor inhibitors (TNFi) and non-TNFi). Minimally clinical improvement (MCI) in RAPID3 was defined as a decrease of ≥3.2 points during followup. Differences between medication usage, biologic switch, and RAPID3 improvement between race and ethnicity groups while on biologics, was investigated. <h3>Results</h3> 1040 subjects with 3719 follow-up visits spanning an average of 63.2 weeks were analysed. African Americans and Hispanics comprised 24% and 15%, respectively. Compared to Whites, African Americans and Hispanics had significantly less education (p&lt;0.001 for both), significantly less biologic use (p&lt;0.001 for both) and significantly less TNF use (p&lt;0.001 for both). African Americans had significantly higher RAPID3 scores at enrollment than Whites as well (p=0.018). Switching between TNFi and non-TNFi was recorded in only 9 subjects, with 7 subjects switching from TNFi to non-TNFi. There was no statistical difference between race/ethnic groups in frequency of bDMARD switching, nor within bDMARD class (TNFi class, p=cc; non-TNFi class, p=bb). bDMARD treatment led to MCI in RAPID3 in 101 (38%) subjects and in more African Americans (29 [48%]) and Hispanics (12 [41%]) than in Whites (49 [37%]) (but not statistically significant). <h3>Conclusions</h3> In our cohort, disparity was seen in bDMARD use between race and ethnic groups but had similar and infrequent biologic switch. Based upon these data, efforts to eliminate biologic use disparity remains paramount and supersedes concerns regarding disparity in biologic switching. <h3>Disclosure of Interest</h3> G. Kerr Grant/research support from: BMS, Genentech, Pfizer, C. Swearingen Grant/research support from: BMS, Genentech, Pfizer, S. Hochberg: None declared, J. Ude: None declared, Y. Yazici Grant/research support from: BMS, Genentech, Pfizer
Large B-Cell Lymphomas in Pediatric and Young Adults Display Clinically Relevant Molecular Features Distinguishable from Adult Counterparts
Authors: Joan Enric Ramis-Zaldivar, Blanca Gonzalez-Farre, Balagué Olga, Verónica Celis, Ferran Nadeu, Mara Andrés, Idoia Martin-Guerrero, Marta Garrido, Ayman Gaafar, Mariona Suñol, Carmen Bárcena, Federico Garcia-Bragado, Maitane Andión, Daniel Azorín, Itziar Astigarraga, Maria Sagaseta, Constantino Sábado, Soledad Gallego, Jaime Verdú, Raphael F Delgado, Gustavo Tapia, Alfredo Rivas-Delgado, Ivan Dlouhy, Julia Salmerón-Villalobos, Guillem Clot, Anna Enjuanes, Armando Lopez-Guillermo, Pallavi Galera, Matthew J. Oberley, Leticia Quintanilla-Martinez, Elaine S. Jaffe, Elias Campo, Itziar Salaverria
Journal: Blood (2018)
AB0847 Impact of spondyloarthritis on life quality: before and after treatment
Authors: X. Grapton, P. Lemesle, L. Arabian, V. Strotz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Life quality issues in spondyloarthritis (SPA) are often spontanously mentioned by patients or identified by rheumatologists. Besides classic follow up parameters, we have to consider those issues to improve our patients life quality. <h3>Objectives</h3> Explore and quantify the impact of SPA on life quality via everyday’s life and psychological items and the effect of treatment on them. <h3>Methods</h3> SPA cases were collected by a group of 14 private practice rheumatologists (Rh) in the Paris area. Basic informations about the patient and his disease were provided by his rheumatologist. Questionnaire including 12 themes and 41 items was filled in by the patient. <h3>Results</h3> 50 cases collected, 59.5% men, mean age 45 years, 82% working Axial SPA 42%, peripheric 4%, mixt 52%. Mean duration before study: 14 years. Moderate disease 57%, severe 26,5%. HLA B27 positive 84% Drugs: NSAIDS 96%, classic DMARDS 31%, biological DMARDS 84%, corticosteroids 36%, combination therapy 42%. Associated measures were suggested by the Rh: Physical activity (62%), rest (56%), psychological support, physiotherapy, yoga, adapting professionnel activity and environment… Life quality issues are spontaneously mentioned by 40% of the patients. Before treatment, 72% of the patients report consequences on their hobbies, 68% on their psychological well-being, 54% on their getting about, 50% on their family relations. The less impacted items are food (26%) and economy (24%). Life quality is mostly altered by pain (71%), then fatigue (17%), handicap (7%) and other people’s attitude (5%). After treatment, social repercussions diminish by 47%, then getting about, housework, family relations, holidays, sexual life, psychological well-being, hobbies and work (between −21% and −44%). Drug intolerance: 36%. The items improving by more than 50% after treatment are in this order: cultural life, transports, house-keeping, do-it-yourself, sleep, going out, work (53% less sick leave). The treatment is less efficient (&lt;22%) on economy, dependance, disillusion, depression and sexual life. Family circle lacks empathy in 66% of the cases, family relations stay difficult after treatment. <h3>Conclusions</h3> SPA diminishes quality of life in 75% of our patients, but only 40% mention it spontaneously. All the parameters impacted by SPA were significantly improved after treatment. The best improvement concerned hobbies, including culture, do-it-yourself and going out. One patient of two found correct sleep and felt psychologically better. Sick leave was reduced by half, but, unfortunately, family relations didn’t improve. The rheumatologist has to track, in a trusting patient-physician relation, the daily situation impacted by the SPA. <h3>Disclosure of Interest</h3> None declared
Abstract IA02: Modeling sarcoma susceptibility: The Li-Fraumeni syndrome paradigm
Authors: David Malkin
Journal: Clinical Cancer Research (2018)

Abstract The original description of Li-Fraumeni syndrome (LFS) 1969 was generated from the ascertainment of medical and death records of over 600 children with rhabdomyosarcoma. Although the clinical definition of LFS has evolved over the decades, the occurrence of sarcoma in at least one affected TP53 gene mutation carrier is common to many families. However, the genotype:cancer phenotype association of sarcomas in mutation carriers remains poorly understood. This lecture will review some of the phenotypic characterizations of sarcomas in LFS and explore recent exciting advances that suggest a role for various genetic/genomic and epigenetic modifiers of the underlying germline TP53 mutation in defining these clinical phenotypes. The challenges and opportunities to enhance early tumor detection and modify disease risk will also be discussed. Citation Format: David Malkin. Modeling sarcoma susceptibility: The Li-Fraumeni syndrome paradigm [abstract]. In: Proceedings of the AACR Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; May 16-19, 2017; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(2_Suppl):Abstract nr IA02.
AB1386 Physician awareness of rheumatic immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Authors: F. Araújo, J.E. Fonseca
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Immune checkpoint inhibitors (ICI) are novel and promising therapies for the treatment of a range of cancer types, acting through stimulation of the patient's immune system to engage on tumour cells. This enhanced immune system may potentially cross-react against any organ system, and reporting of rheumatic immune-related adverse events (irAE) has been growing. <h3>Objectives</h3> To evaluate awareness of treatment with ICI and rheumatic irAE among Portuguese rheumatologists and oncologists. <h3>Methods</h3> A web-based questionnaire was sent in November 2017 to members of the Portuguese Society of Rheumatology and Portuguese Society of Oncology. Aside from demographic variables, assessed domains included awareness and clinical experience with ICI and irAE, as well as educational needs on the topic and interest in participating in multidisciplinary approaches. <h3>Results</h3> Response rates were 61/221 (27.6%) for rheumatologists and 13/653 (2.0%) for oncologists. Demographics were similar in both groups, including mean age (39.9 and 41.1 years) and female gender (59% and 53.8%), respectively; the majority were consultant physicians (67.2% and 69.2%) working at public hospitals (86.9% and 92.3%), respectively. Regarding ICI, most rheumatologists had heard of but were unfamiliar (63.9%) while most oncologists were at least moderately familiar (92.3%) with such therapies. Almost all physicians were aware but more oncologists reported having patients with rheumatic irAE (46.2 vs 4.9%); the most frequent were arthralgia and arthritis. These physicians were all moderately or very confident in managing these irAE. Most physicians considered that Rheumatology-Oncology multidisciplinary approaches would be of benefit and were interested in participating. Education on pathophysiology, epidemiology, clinical assessment and treatment was deemed necessary. Table 1 summarises the main results. <h3>Conclusions</h3> Most rheumatologists had limited knowledge of ICI and limited experience with rheumatic irAE, compared to oncologists. Both groups considered that the development of multidisciplinary teams would be beneficial to allow timely assessment and referral of these patients. Despite limited by the response rate (particularly low for oncologists) and response bias, this study emphasises the need for specific education on ICI and irAE, especially for Portuguese rheumatologists. <h3>Disclosure of Interest</h3> None declared
FRI0466 Articular affection in systemic sclerosis: correlation of ultrasound findings with clinical, biological and radiographical findings
Authors: C. De la Puente, J. Quiñones, S. Zegarra
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To evaluate the prevalence of subclinical synovitis in systemic sclerosis (SS), as well as the correlation of sonographic findings in hands with radiographs and with clinical-analytical parameters. In addition, the correlation with scales of functionality will be determined. <h3>Methods</h3> Cross-sectional observational-analytical study that included 40 patients with ES and 23 patients with rheumatoid arthritis (RA) as a control group during the period 10/2015–03/2016. Clinical, analytical, immunological, ultrasound and the radiological characteristics of both groups and their respective statistical correlations were compiled. <h3>Results</h3> The mean age of the group with SS was 53.3±14.1 years; 87.5% were women and 75% of the cases were cutaneously limited. The average time of evolution of the disease was 6.8 years from the diagnosis. Regarding the clinical joint involvement in the carpus and hands, frank arthritis was present in 16 cases (40%), with an average of DAN: 3.77 and TAN: 1.57; with an average of EVA global pain: 30/100 and elevated CRP in 42.5% of cases. The prevalence of subclinical synovitis with ultrasound expression of synovial effusion ±synovial hypertrophy in the SS group was at carpal level (77%), FCM (60%), PFI 32.5%) and DFI (15%). The statistical linear correlation between findings of cortical erosions at the ultrasound level versus the radiological data was positive only in the involvement at the joint level FCM and FID. In the group with SS, the HAQ questionnaire had an average of 0.95 (mild disability) versus 0.77 in the RA group, and the average hand function score or Cochin index: 20.6 (moderate disability) against 17.5 of the RA group. There was no statistically significant correlation (χ²) between the elevated CRP values and these 2 questionnaires in the SS group. The radiological findings of calcinosis and acroosteólisis in the group with SS were double the cases of the group with RA (7 versus 3, and 14 versus 7 respectively). <h3>Conclusions</h3> Subclinical joint involvement in systemic sclerosis had a high prevalence, similar in rheumatoid arthritis, with ultrasound being a fundamental test when evaluating subclinical inflammatory activity. It also presents an important correlation with the findings found in radiographs in the same locations. <h3>Disclosure of Interest</h3> None declared